2-ethyl-7-methoxy-1,2,3,4-tetrahydro-isoquinoline

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 英文名称: 2-ethyl-7-methoxy-1,2,3,4-tetrahydro-isoquinoline
• 英文别名: 2-Aethyl-7-methoxy-1,2,3,4-tetrahydro-isochinolin；2-ethyl-7-methoxy-3,4-dihydro-1H-isoquinoline
• 化学式: C₁₂H₁₇NO
• 分子量: 191.273
• InChiKey: CSTOTIUMRGKITH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  12.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  7-甲氧基异喹啉 在 盐酸 、 tin 作用下， 生成 2-ethyl-7-methoxy-1,2,3,4-tetrahydro-isoquinoline
  参考文献：
  名称：

  Fritsch, Justus Liebigs Annalen der Chemie, 1895, vol. 286, p. 16

  摘要：

  DOI：

文献信息

• Quinolizidinone M1 Receptor Positive Allosteric Modulators
  申请人：Kuduk Scott D.

  公开号：US20110046145A1

  公开（公告）日：2011-02-24

  The present invention is directed to compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

  本发明涉及式(I)的化合物，其为M1受体正向变构调节剂，并且在治疗M1受体参与的疾病，如阿尔茨海默病、精神分裂症、疼痛或睡眠障碍方面具有用途。本发明还涉及包含该化合物的制药组合物，以及在治疗由M1受体介导的疾病中使用该化合物和组合物。
• Quinolizidinone M1 receptor positive allosteric modulators
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP2268280B1

  公开（公告）日：2013-04-24
• US8173672B2
  申请人：——

  公开号：US8173672B2

  公开（公告）日：2012-05-08
• [EN] QUINOLIZIDINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS<br/>[FR] MODULATEURS ALLOSTÉRIQUES POSITIFS DU RÉCEPTEUR M1 DE LA QUINOLIZIDINE
  申请人：MERCK & CO INC

  公开号：WO2009117283A2

  公开（公告）日：2009-09-24

  The present invention is directed to compounds of formula (I) which are Ml receptor positive allosteric modulators and that are useful in the treatment of diseases in which the Ml receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the Ml receptor.
• Fritsch, Justus Liebigs Annalen der Chemie, 1895, vol. 286, p. 16
  作者：Fritsch

  DOI：——

  日期：——